Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
about
curatedOvarianData: clinically annotated data for the ovarian cancer transcriptomeGene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets.Expression signatures of TP53 mutations in serous ovarian cancers.Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines.The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylationBayesian probit regression model for the diagnosis of pulmonary fibrosis: proof-of-principleBiomarker robustness reveals the PDGF network as driving disease outcome in ovarian cancer patients in multiple studies.Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome.Epigenetic silencing of MAL, a putative tumor suppressor gene, can contribute to human epithelium cell carcinoma.Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent diseaseExpression profile of COL2A1 and the pseudogene SLC6A10P predicts tumor recurrence in high-grade serous ovarian cancer.High levels of genomic aberrations in serous ovarian cancers are associated with better survival.An IL6-correlated signature in serous epithelial ovarian cancer associates with growth factor responseA seven-gene prognostic model for platinum-treated ovarian carcinomas.Clinically relevant microRNAs in ovarian cancerMultidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinomaAnalysis of PSPHL as a Candidate Gene Influencing the Racial Disparity in Endometrial Cancer.Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinomaRisk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis.Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.Validation of ovarian cancer gene expression signatures for survival and subtype in formalin fixed paraffin embedded tissuesOvarian cancer: involvement of the matrix metalloproteinases.Microarray-based gene expression studies in ovarian cancer.Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.Ovarian cancer: a bright future.Regulatory network involving miRNAs and genes in serous ovarian carcinoma.
P2860
Q30611147-E7B206E7-D43D-4785-AF26-1D81763B40A4Q33543156-54744727-C0C9-4C08-AD94-6164EB9BF3ECQ33588196-82AC2391-E6DA-4A8A-B9D1-6B576FA5930BQ33781661-DFE0BAB7-5967-46A6-8618-4625C2700A8DQ34029565-654C9026-AF32-48A5-8A13-70F2AAE40507Q34040907-92B9326E-BCD8-4600-8CF1-347D4A7F97DFQ34124475-14C9C740-E0B6-4ACF-9733-64CFFD4E9282Q34166257-FD15A033-27A4-4F6E-B013-B25CA01FE450Q34410542-7D52A1F9-9694-4258-9D58-5B5685C3B8E7Q34411194-333604BE-20D7-4B02-BC4C-925A095B1182Q34491120-11E99E91-12C3-4721-AC88-9E549846CD37Q34571142-F4962FE4-BC9A-4936-BD69-892657848B3BQ34868121-6AE9F8F5-A798-424F-BAFB-FA6CEE51A06EQ35125629-BA6885ED-0153-424D-9D40-8EFC473CAA6AQ35204609-967F14D5-FB75-4639-ABDB-9D568DCD6B46Q36037099-0EF344EE-F622-4724-B4DC-616B663254DBQ36075163-8CF5333F-B723-4EA5-9E20-DBA3B8E7EA16Q36103829-162CB7F9-6216-405C-AE04-62A0E823CB6AQ36199823-E1EF28FC-F961-43B3-9F92-73BC5C88DAC9Q36381924-A91EAF6D-10B8-4D8E-9631-24C943137DCDQ37000936-22BB3E20-BEBE-4942-BB9D-990A45CF35C0Q37069498-39A986E8-CBD4-4254-BFDE-A24498030EACQ37113828-77095B37-3E92-46D9-AEB0-8E2D9DB80878Q37832928-BDE04F19-A3BC-4BFD-A81B-4CBB39BDDAB6Q39430345-29D5E4DA-A480-4496-AD12-A4016965DA9CQ44356847-6AB183D5-5051-48E9-BD0B-44F65D2F3F4FQ45874094-FCEEA82D-F424-4B99-9C5E-68DF6D628D51
P2860
Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Microarray analysis of early s ...... edictive of favorable outcome.
@ast
Microarray analysis of early s ...... edictive of favorable outcome.
@en
Microarray analysis of early s ...... edictive of favorable outcome.
@nl
type
label
Microarray analysis of early s ...... edictive of favorable outcome.
@ast
Microarray analysis of early s ...... edictive of favorable outcome.
@en
Microarray analysis of early s ...... edictive of favorable outcome.
@nl
prefLabel
Microarray analysis of early s ...... edictive of favorable outcome.
@ast
Microarray analysis of early s ...... edictive of favorable outcome.
@en
Microarray analysis of early s ...... edictive of favorable outcome.
@nl
P2093
P2860
P1476
Microarray analysis of early s ...... edictive of favorable outcome.
@en
P2093
Andrew Berchuck
Douglas A Levine
Edwin S Iversen
Hisani Horne
Holly K Dressman
Jason C Barnett
Jeffrey R Marks
Jennifer P Clarke
Jingqin Luo
P2860
P304
P356
10.1158/1078-0432.CCR-08-2430
P407
P577
2009-03-24T00:00:00Z